Business Description
Nanexa AB
ISIN : SE0007074166
Total Employee Number:
16Compare
Compare
Traded in other countries / regions
NANEXA.Sweden40M.Germany IPO Date
2021-02-12Description
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 66.11 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 27.99 | |||||
Beneish M-Score | -2.8 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 55 | |||||
3-Year EPS without NRI Growth Rate | 60.8 | |||||
3-Year FCF Growth Rate | 43.8 | |||||
3-Year Book Growth Rate | -33.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90 | |||||
9-Day RSI | 83.94 | |||||
14-Day RSI | 79.79 | |||||
3-1 Month Momentum % | -15.52 | |||||
6-1 Month Momentum % | 1.86 | |||||
12-1 Month Momentum % | 97.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.89 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 2.5 | |||||
Days Sales Outstanding | 67.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -47.5 | |||||
Shareholder Yield % | -5.97 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 152.64 | |||||
Operating Margin % | -67.39 | |||||
Net Margin % | -72.54 | |||||
EBITDA Margin % | -27.59 | |||||
FCF Margin % | -99.16 | |||||
OCF Margin % | -18.64 | |||||
ROE % | -23.22 | |||||
ROA % | -17.54 | |||||
ROIC % | -21.47 | |||||
3-Year ROIIC % | 1956.04 | |||||
ROC (Joel Greenblatt) % | -207.08 | |||||
ROCE % | -19.45 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 28.38 | |||||
PB Ratio | 8.29 | |||||
Price-to-Tangible-Book | 18.47 | |||||
EV-to-EBIT | -48.61 | |||||
EV-to-EBITDA | -116.37 | |||||
EV-to-Revenue | 32.1 | |||||
EV-to-FCF | -32.19 | |||||
Price-to-GF-Value | 2.92 | |||||
Price-to-Median-PS-Value | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 27.7 | |||||
| Price-to-Net-Cash | 27.7 | |||||
Earnings Yield (Greenblatt) % | -2.06 | |||||
FCF Yield % | -2.97 |
Nanexa AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanexa AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 170 days | ||
| Third quarter earnings results for 2026 | 2026-10-21 | In 49 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 13:00 | 0.39 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-27 | 0.39 (+0.00%) | ||
| General meeting for 2025 | 2026-05-12 15:00 | 0.31 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 0.33 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 0.30 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 | 0.31 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-10-21 | 0.16 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 0.17 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nanexa AB
No articles.